Literature DB >> 17715500

Eculizumab.

Charles J Parker, Santwana Kar, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17715500     DOI: 10.1038/nrd2369

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  17 in total

1.  Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury.

Authors:  Yuko Kimura; Lin Zhou; Takashi Miwa; Wen-Chao Song
Journal:  J Clin Invest       Date:  2010-10       Impact factor: 14.808

2.  Eculizumab.

Authors:  Eline A Dubois; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

3.  The discovery of medicines for rare diseases.

Authors:  David C Swinney; Shuangluo Xia
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

Review 4.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

Review 5.  Complement inhibitors to treat IgM-mediated autoimmune hemolysis.

Authors:  Diana Wouters; Sacha Zeerleder
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

6.  Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19.

Authors:  Sokratis A Apostolidis; Amrita Sarkar; Heather M Giannini; Rishi R Goel; Divij Mathew; Aae Suzuki; Amy E Baxter; Allison R Greenplate; Cécile Alanio; Mohamed Abdel-Hakeem; Derek A Oldridge; Josephine Giles; Jennifer E Wu; Zeyu Chen; Yinghui Jane Huang; Ajinkya Pattekar; Sasikanth Manne; Oliva Kuthuru; Jeanette Dougherty; Brittany Weiderhold; Ariel R Weisman; Caroline A G Ittner; Sigrid Gouma; Debora Dunbar; Ian Frank; Alexander C Huang; Laura A Vella; John P Reilly; Scott E Hensley; Lubica Rauova; Liang Zhao; Nuala J Meyer; Mortimer Poncz; Charles S Abrams; E John Wherry
Journal:  bioRxiv       Date:  2021-05-03

Review 7.  Role of C5 activation products in sepsis.

Authors:  Peter A Ward
Journal:  ScientificWorldJournal       Date:  2010-12-14

8.  Antibody-mediated rejection in heart transplantation: case presentation with a review of current international guidelines.

Authors:  Octavio E Pajaro; Dawn E Jaroszewski; Robert L Scott; Anantharam V Kalya; Henry D Tazelaar; Francisco A Arabia
Journal:  J Transplant       Date:  2011-12-06

Review 9.  Transition metal catalyzed [6 + 2] cycloadditions.

Authors:  Amit Anand; Prabhpreet Singh; Vipan Kumar; Gaurav Bhargava
Journal:  RSC Adv       Date:  2019-08-15       Impact factor: 4.036

Review 10.  Complement system in dermatological diseases - fire under the skin.

Authors:  Jaana Panelius; Seppo Meri
Journal:  Front Med (Lausanne)       Date:  2015-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.